Geode Capital Management
CVKD icon

Geode Capital Management’s Cadrenal Therapeutics CVKD Stock Holding History

Geode Capital Management’s Portfolio CVKD Stock Details CVKD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$111K Buy
21,626
+7,098
+49% +$49.8K ﹤0.01% 4108
2025
Q4 		$98.5K Buy
14,528
+1,818
+14% +$20.6K ﹤0.01% 4103
2025
Q3 		$175K Hold
12,710
– – ﹤0.01% 3967
2025
Q2 		$153K Buy
12,710
+624
+5% +$9.27K ﹤0.01% 3953
2025
Q1 		$213K Buy
12,086
+1,532
+15% +$28.2K ﹤0.01% 3828
2024
Q4 		$153K Buy
+10,554
New +$152K ﹤0.01% 3977
2024
Q3 		– Sell
-4,104
Closed -$28.9K – 4548
2024
Q2 		$28.9K Buy
4,104
+1,246
+44% +$8.62K ﹤0.01% 4394
2024
Q1 		$26.1K Buy
2,858
+275
+11% +$3.49K ﹤0.01% 4445
2023
Q4 		$27.6K Hold
2,583
– – ﹤0.01% 4461
2023
Q3 		$26.4K Buy
+2,583
New +$36.7K ﹤0.01% 4569

Other funds holding CVKD

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
DWP
Destiny Wealth Partners Tavares, Florida $914M AUM 18.14% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management's CVKD Position: Q1 2026 in Review

Geode Capital Management increased its Cadrenal Therapeutics (CVKD) stake by 49% in Q1 2026, buying an estimated $49.8K and bringing the position to 21,626 shares worth $111K. The position accounts for ﹤0.01% of the portfolio, ranked #4108.

Geode Capital Management first reported a position in CVKD in Q3 2023 and has held it in 10 quarters since. The position peaked at $213K in Q1 2025. 20 funds tracked by Wall St. Rank hold CVKD as of Q1 2026.

  • Geode Capital Management held 21,626 shares of Cadrenal Therapeutics worth $111K as of Q1 2026.
  • Geode Capital Management bought 7,098 Cadrenal Therapeutics shares in Q1 2026, an estimated $49.8K.
  • Cadrenal Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #4108 holding.
  • Geode Capital Management first reported a position in Cadrenal Therapeutics in Q3 2023 and has held it in 10 quarters since.
  • Geode Capital Management's Cadrenal Therapeutics position peaked at $213K in Q1 2025.
  • 20 funds tracked by Wall St. Rank held Cadrenal Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.